Study of OP-1 Putty in Uninstrumented Posterolateral Fusions
NCT ID: NCT00678353
Last Updated: 2011-06-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
202 participants
OBSERVATIONAL
2007-05-31
2007-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Pilot Study of the OP-1 Putty in Uninstrumented Posterolateral Fusions
NCT00679107
OP-1 Putty for Posterolateral Fusions
NCT00677950
OsteoStrux™ Collagen Ceramic Scaffold in Instrumented Lumbar Spine Fusion
NCT01873586
A Pilot Study to Evaluate an Osteogenic Protein 1 (OP-1) Putty Spinal System and an Autograft Spinal System
NCT00678171
Post Marketing Study of MagnetOs Putty Compared to Local Autograft in Patients Undergoing Posterolateral Lumbar Fusion
NCT04679896
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Follow-up to S01-01US, conducted to expand information
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The patient or legal guardian is willing and able to understand, sign and date the study specific Patient Informed Consent.
3. The patient agrees to complete the necessary clinical and radiographic evaluations.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Olympus Biotech Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Olympus Biotech
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Santa Monica, California, United States
Stanford, California, United States
Denver, Colorado, United States
Clearwater, Florida, United States
Fort Lauderdale, Florida, United States
Chicago, Illinois, United States
Kalamazoo, Michigan, United States
Southfield, Michigan, United States
St Louis, Missouri, United States
New York, New York, United States
Rochester, New York, United States
Charlotte, North Carolina, United States
Akron, Ohio, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Germantown, Tennessee, United States
San Antonio, Texas, United States
Charlottesville, Virginia, United States
Fairfax, Virginia, United States
Halifax, Nova Scotia, Canada
London, Ontario, Canada
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
06-UPLF-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.